A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.
Saved in:
| Title: | A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. |
|---|---|
| Authors: | Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Desai NV; Harvard Medical School, Boston, MA, USA.; Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Li T; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Poorvu PD; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sinclair N; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Dana-Farber/Brigham and Women's Cancer Center at Milford, Milford, MA, USA., Spring LM; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA., Faggen M; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Dana-Farber/Brigham and Women's Cancer Center at South Shore Hospital, South Weymouth, MA, USA., Constantine M; Harvard Medical School, Boston, MA, USA.; Hematology/Oncology, Dana-Farber/Brigham and Women's Cancer Center at Milford, Milford, MA, USA., Metzger O; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Alberti J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Deane J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Clinical Affairs, TransMedics, Inc, Andover, MA, USA., Rosenberg SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA., Frank E; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Yale Cancer Center, New Haven, CT, USA., Tung NM; Harvard Medical School, Boston, MA, USA.; Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Tayob N; Harvard Medical School, Boston, MA, USA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., King TA; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Mittendorf EA; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Eric.winer@yale.edu.; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. Eric.winer@yale.edu.; Harvard Medical School, Boston, MA, USA. Eric.winer@yale.edu.; Yale Cancer Center, New Haven, CT, USA. Eric.winer@yale.edu. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2022 May 10; Vol. 8 (1), pp. 63. Date of Electronic Publication: 2022 May 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
